Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Organon ( (OGN) ).
Organon & Co. announced that the FDA has extended the review date for VTAMA® cream, used for treating atopic dermatitis, to March 12, 2025, without raising safety concerns. This extension impacts the company’s financial outlook for 2025, with expected revenue contributions and potential effects on earnings. Organon remains confident in the cream’s efficacy and is committed to providing the FDA with necessary information for approval.
See more data about OGN stock on TipRanks’ Stock Analysis page.
